Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Phase 2
Completed
- Conditions
- Genetic Disorders
- Interventions
- Drug: i.v. recombinant human C1 inhibitor
- Registration Number
- NCT00262288
- Lead Sponsor
- Pharming Technologies B.V.
- Brief Summary
The purpose of this multi-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Recombinant Human C1INH i.v. recombinant human C1 inhibitor -
- Primary Outcome Measures
Name Time Method Primary outcomes: Relief of angioedema symptoms 24 hours
- Secondary Outcome Measures
Name Time Method Secondary outcomes: Safety and tolerability; pharmacokinetics/pharmacodynamics 90 days
Trial Locations
- Locations (1)
For information on sites in Europe, please contact Pharming Technologies.
🇳🇱Leiden, Netherlands